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ABSTRACT 
Objective: To evaluate the use of MET in ovulation induction and pregnancy rates in a woman with polycystic ovary syndrome (PCOS). 
Methods: A meta-analysis of randomised clinical trials (RCT) that presented ovulation and gestation rates in women with PCOS, after administering 
CC or M et al. one or combined was performed. The studies were selected according to the inclusion criteria in PCOS patients, resistant to CC or not. 
Results: The meta-analysis demonstrated that MET and CC did not significantly increase the ovulation (Odds Ratio 1.72 [0.71, 4.12]) and gestation 
(OR 1.33 [0.88, 2.02]) rates when compared to the usage of CC itself in women not resistant to CC. However, in women with CC-resistant PCOS, the 
group treated with CC and MET presented higher rates of ovulation (Odds Ratio = 14.57 [4.96, 42.81]) and gestation (Odds Ratio = 11.86 [2.45, 
57.36]) than patients treated only with CC. 
Conclusion: The combination of MET and CC did not show advantages over the administration of CC alone in women not resistant to CC. However, 
MET may show satisfactory results in women resistant to CC. 
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Polycystic ovary syndrome (PCOS) is the most common hormonal and 
metabolic disorder among women in fertile age. It is clinically and/or 
biochemically characterised by hyperandrogenism, oligo or amenorrhea 
and ovaries with polycystic morphology [1]. Therefore, anovulation and 
consequently infertility are some of the symptoms of PCOS patient’s [2]. 
In these cases, to treat anovulation, CC is the first-line therapy used [3, 4]. 
Its usage results in ovulation in about 75-80% of patients [5], in which 
only 33-45% of them get pregnant [6]. For patients that do not respond 
to the treatment with CC, other options are possible, like therapies with 
gonadotropin, bromocriptine, tamoxifen, dexamethasone, and 
laparoscopic ovarian drilling [7]. However, it is also recommended the 
addition of MET to the therapy with CC, for patients who had not initially 
responded to the treatment with CC alone [8]. 
The treatment of choice for infertility in PCOS patients would be the 
combination of Metal ong with CC [9]. Nonetheless, in randomised 
clinical trials [10], it was also settled that the MET combined with CC 
is an effective treatment, both in ovulation induction and in reaching 
gestation in women affected by PCOS. 
The usage of MET has been persistently cited as an important 
treatment for infertility caused by PCOS [3, 4, 11-13]. 
MET is a biguanide used mainly in noninsulin-dependent diabetes 
mellitus patients. Its usage in PCOS is owing to the decrease of high 
concentrations of insulin, which consequently reduces androgens 
production, though regularising the production of estrogens and 
restoring the ovarian hormonal balance [14]. 
Therefore, the aim of this study was to evaluate the relation of MET 
to the induction of ovulation in PCOS patients. 
MATERIALS AND METHODS 
For the systematic review, searches on the following electronic 
databases were carried: Cochrane, Lilacs, Scielo, Scopus, Science 
Direct, and PubMed. A time limit for the search was not established, 
and the used strategies were Metformin and fertility and 
“randomized clinical trial”; Metformin and “ovulation induction” and 
“randomized clinical trial” and Metformin and “polycystic ovary 
syndrome” and “randomized clinical trial”. Publications available in 
English, Spanish and Portuguese, were evaluated. All studies were 
randomized clinical trials that compared the use of metformin 
versus clomiphene citrate or metformin and clomiphene citrate 
versus isolated clomiphene citrate. The evaluated outcomes were 
ovulation rate, gestation rate, as well as patients with definitive 
diagnostic of PCOS, with no other comorbidity that could 
compromise their fertility.  
The studies should also present a clear definition of resistance, or 
not, to the usage of isolated CC, since the comparison between the 
uses of this drug in resistant and non-resistant patients is part of the 
current meta-analysis approach. Following PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) 
recommendations titles and abstracts of records retrieved were 
initially screened and the full text of those considered relevant was 
then analysed. The literature selection process was conducted by 
two independent reviewers (Steimbach L. M. e Loução A. S.), with a 
third reviewer in the case of discrepancies (Sanches A. C. C.). 
No studies were not excluded by quality methodological reasons.  
The meta-analysis was done according to Cochrane’s 
recommendations and with the help of Review Manager 5.2 
software. Odds Ratio (OD) was calculated to summarise all 
outcomes, with 95% confidence intervals (CI). The statistic was 
random effects with Inverse of the Variance (IV) and Mantel-
Haenszel (M-H). 
RESULTS AND DISCUSSION 
2586 articles were found on the systematic research (fig. 1), from 
which 1640 were duplicates. Part of these was excluded by the title 
and abstracts reading and part by the full-article evaluation. A total 
of 11 RCT met the inclusion criteria. 
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Fig. 1: Flowchart of included studies 
 
The participants–a total of 1451–of the included studies presented 
an average age of 27.6 y old (25.0±29.5) and body mass index of 32.5 
(25.0±38.0 Kg/m²). 
There was no statistically significant difference between combined 
MET+CC versus CC, in the studies of induction of ovulation and 
gestation in women with no resistance to CC (fig 2 and 3). 
  
 
Fig. 2: Forest plot for ovulation rates in nonresistant patients to clomiphene citrate. Statistical method: odds ratio (I-V Random, 95% CI). 
Test for overall effect done using review manager software 
 
On fig 2, the global effect–OR 1.72 [0.71, 4.12]–shows that there is no 
favouring of any kind of treatment for the outcome ovulation rate in 
nonresistant women to CC. 
The heterogeneity of the meta-analysis was high (73%), which 
means that there is a great methodological variability among the 
studies. The five studies used in this meta-analysis have a duration 
period and a number of patients very variable among one another, 
which is a reason that contributes to the found heterogeneity. The 
duration of the clinical trials published by Khorram et al. 2006 and 
Raja et al. 2005 were different and lasted 1 mo and 6 mo, 
respectively. The others presented time horizons between two and 
four years. The hypothetical removal of these two studies reduced 
the heterogeneity to 0%, without altering the result, though. 
 
 
Fig. 3: Forest plot for gestation rates in nonresistant patients to clomiphene citrate. Statistical method: odds ratio (M-H Random, 95% CI). 









Heterogeneity: Tau² = 0.64; Chi² = 15.05, df = 4 (P = 0.005); I² = 73%











































Metformim+CC CC Odds Ratio Odds Ratio
IV, Random, 95% CI












Heterogeneity: Tau² = 0.08; Chi² = 7.22, df = 5 (P = 0.20); I² = 31%







Heterogeneity: Tau² = 0.27; Chi² = 4.55, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 1.66 (P = 0.10)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.41; Chi² = 28.99, df = 8 (P = 0.0003); I² = 72%
Test for overall effect: Z = 0.07 (P = 0.94)















































































Metformin+CC CC Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
CC Metformin+CC
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The meta-analysis for the outcome of gestation in nonresistant patients 
to CC showed an overall effect of OR 1.33 [0.88, 2.02] and a moderate 
heterogeneity (31%). This result is completely modified by the 
hypothetical removal of Moll et al. (2006) study, from which a 0% 
heterogeneity is obtained, as well as a result that favours the combined 
treatment of MET+CC (Odds Ratio = 1.58 [1.12, 2.24]). It occurs because 
Moll et al. (2006) is the only study that presents the greater percentage 
of events favouring the treatment with CC only, while the combined 
treatment is favoured within all the other studies. In this study, each 
woman was evaluated by several cycles in which they had the 
clomiphene dosage increased from 50 to 150 mg a day. So the reason of 
the cumulative ovulation was evaluated, not the number of cycles. This 
unique methodological difference justifies the heterogeneity found 
because all other included articles evaluate each patient for six cycles. 
The evaluation of gestation rates compared between MET versus CC 
shows no differences that could favour any of the treatments.  
Though, the hypothetical removal of a study made by Johnson et al. 
(2010) reduced the heterogeneity from 56% to 0% and favoured the 
treatment with CC only (Odds Ratio: 0.34 [0.21, 0.55]). This can be 
justified because the results in the study favoured the treatment 
with MET only. Studies published by Legro, 2007 and Zain, 2009 
have a smaller number of MET+CC patients compared with the 
patients from the CC group, while Johnson et al. has the same 
number of patients in both groups. 
Several authors have not found statistically significant evidence that 
could favour the outcome of gestation in neither of the treatments 
(MET or CC) [15-17]. 
The meta-analysis from studies with patients resistant to CC 
presented a statistically significant result, favouring the usage of 
MET+CC, (fig 4 and 5). In both meta-analyses, the heterogeneity was 
0%, which shows there are no methodological or statistical 
differences among themselves and that the result is robust. The 
resistance to CC is defined in these studies as the non-ovarian 
response to the usage of 150 mg of this drug for 5 straight days, 
during 3 consecutive menstrual cycles. 
 
 
Fig. 4: Forest plot for ovulation rates in resistant patients with clomiphene citrate: odds ratio (M-H random, 95% CI). Test for overall 
effect done using review manager software 
 
Similar results were observed in another meta-analysis in which OR 
= 1.27 [1.03, 1.56] [18]. However, this study does not report the 
existence or not of resistance to CC, which methodologically 
differentiates it from the current study. 
 
 
Fig. 5: Forest plot for gestation rates in resistant patients to Clomiphene Citrate. Statistical method: odds ratio (M-H random, 95% CI). 
Test for overall effect done using review manager software 
 
Results obtained in other studies agree with the ones described 
above and also demonstrates that patients resistant to CC present 
better results when MET is combined with CC [19, 20]. There is an 
evident increase on ovulation rates (OR = 1.6, 95% CI 1.2-2.1, p = 
0.0009 and (OR = 7.31, 95%CI: 2.57-20.76, P<0.0dx5) and gestation 
rates (OR = 1.3, 95% CI 1.0-1.6, p = 0.05) (OR = 7.93, 95%CI: 2.45-
25.63, P<0.05) that can benefit patients.  
CONCLUSION 
MET can be administered concomitantly to the usage of CC, so 
satisfactory results are obtained in patients resistant to CC, by 
increasing the ovulation and gestation rates, when compared to 
the usage of CC only. Yet, in patients that do not present 
resistance to CC, the usage of MET as an adjuvant on the 
treatment does not present statistically significant results that 
would favour its usage. 
CONFLICTS OF INTERESTS 
The authors declare they have no conflicts of interest. 
REFERENCES  
1. Gődény S, Csenteri O. Importance of the interdisciplinary, 
evidence-based diagnosis of polycystic ovary syndrome. Orv 
Hetil 2014;155:1175-88. 
2. Díaz JFJ, González CO. Síndrome de ovario poliquístico. Rev 
Mexicana Med Reproducción 2011;4:51-62.  
3. AL-Inany H, JOHNSON N. Drugs for anovulatory infertility in 
polycystic ovary syndrome: reserve metformin for second line 
treatment for women with clomifene resistance. Br Med J 
2006;332:1461–2.  
4. SEMPR: Serviço de endocrinologia e metabologia–hospital das 
clínicas da universidade federal do paraná. Disponível em: 
Available from http://www.sempr.org.br/protocolos/ proto-
colo06.asp. [Last accessed on 17 Mar 2014]. 
5. Amin M, Abdel-Kareem O, Takekida S, Moriyama T, Abdel-Aal G, 
MARUO T. Update management of non-responder to 
clomiphene citrate in polycystic ovary syndrome. Kobe J Med 






Heterogeneity: Chi² = 0.68, df = 1 (P = 0.41); I² = 0%

























Metformim+CC CC Odds Ratio Odds Ratio
M-H, Fixed, 95% CI








Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 2 (P = 0.94); I² = 0%































Metformin+CC CC Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
CC Metformin+CC
Sanches et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 11, 86-89 
 
89 
6. Costello MF, Eden JA. A systematic review of the reproductive 
system effects of metformin in patients with polycystic ovary 
syndrome. Fertil Steril 2003;79:1–13.  
7. Kazerooni T, Ghaffarpasand F, Kazerooni Y, Setoodeh S. Short-
term metformin treatment for clomiphene citrate-resistant 
women with polycystic ovary syndrome. Int J Gynaecol Obstet 
2009;107:50-3.  
8. American College of Obstetricians and gynaecologists (ACOG). 
management of infertility caused by ovulatory dysfunction. 
Washington, DC. Practice bulletin; 2002. p. 34. 
9. Panidis D, Tziomalos K, Papadakis E, Katsikis I. Infertility 
treatment in polycystic ovary syndrome: lifestyle interventions, 
medications and surgery. Front Horm Res 2013;40:128-41.  
10. Abu Hashim H, EL Lakany N, Sherief L. 
Combined metformin and clomiphene citrate versus laparoscopic 
ovarian diathermy for ovulation induction in clomiphene-
resistant women with polycystic ovary syndrome: a randomised 
controlled trial. J Obstet Gynaecol Res 2011;37:169-77. 
11. Begum MR, Akhter S, Ehsan M, Begum MS, Khan F. 
Pretreatment and co-administration of the oral anti-diabetic 
agent with clomiphene citrate or rFSH for ovulation 
induction in clomiphene-citrate-resistant polycystic ovary 
syndrome. J Obstet Gynaecol Res 2013;39:966-73.  
12. Moll E, bossuyt PMM, Korevaar JC, Lambalk CB, Van Der Veen F. 
Effect of clomifene citrate plus metformin and clomifene citrate 
plus placebo on induction of ovulation in women with newly 
diagnosed polycystic ovary syndrome: randomised double-
blind clinical trial. Br Med J 2006;332:1485.  
13. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. 
Metformin therapy in polycystic ovary syndrome reduces 
hyperinsulinemia, insulin resistance, hyperandrogenemia, and 
systolic blood pressure while facilitating normal menses and 
pregnancy. Metabolism 1994;43:647-54.  
14. Santana LF, Ferriani RA, Sá MFS, Reis RM. Tratamento da infer 
tilidate em mulheres com síndrome dos ovários policísticos. 
Rev Bras Ginecol Obstet 2008;30:201-9. 
15. Johnson N. Metformin is a reasonable first-line treatment 
option for non-obese women with infertility related to 
anovulatory polycystic ovary syndrome--a meta-analysis of 
randomised trials. Aust N Z J Obstet Gynaecol 2011;51:125-9.  
16. Misso ML, Costello MF, Garrubba M, Wong J, Rombauts L, Melder 
AM, et al. Metformin versus clomiphene citrate for infertility in 
non-obese women with polycystic ovary syndrome: a systematic 
review and meta-analysis. Hum Reprod Update 2013;19:2-11. 
17. Xiao J, Chen S, Zhang C, Chang S. The effectiveness 
of metformin ovulation induction treatment in patients with 
PCOS: a systematic review and meta-analysis. Gynecol 
Endocrinol 2012;28:956-60.  
18. Sun X, Zhang D, Zhang W. Effect of metformin on ovulation and 
reproductive outcomes in women with polycystic ovary 
syndrome: a meta-analysis of randomised controlled trials. 
Arch Gynecol Obstet 2013;288:423-30. 
19. Siebert TI, Viola MI, Steyn DW, Kruger TF. 
Is metformin indicated as primary ovulation induction agent in 
women with PCOS? A systematic review and meta-analysis. 
Gynecol Obstet Invest 2012;73:304-13.  
20. Wang LL, Ren W, Cheng QF, Fan XD. Therapeutic effect 
of metformin for clomiphene-resistant infertility patients with 
polycystic ovary syndrome: a systematic analysis. 
Zhonghua Fuchanke Zazhi 2012;47:659-63. 
How to cite this article 
• Laiza Maria Steimbach, Aline Dos Santos Loução, Claudia 
Batista Carraro, Fernanda Stumpf Tonin, Roberto Pontarolo, 
Andreia Cristina Conegero Sanches. Metformin usage to induce 
ovulation in women with polycystic ovary syndrome: a meta-
analysis. Int J Pharm Pharm Sci 2016;8(11):86-89. 
 
